Case management for pediatric respiratory syncytial virus outcomes

Case Manager

Volumn 13, Issue 4, 2002, Pages 72-74

  Deming, Laura M ^a  

^a Memorial Hermann Children's Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; IMMUNOGLOBULIN; PALIVIZUMAB; POLYCLONAL ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; RIBAVIRIN; MONOCLONAL ANTIBODY;

BRONCHIOLITIS; COST BENEFIT ANALYSIS; COUGHING; FEVER; HOSPITALIZATION; HUMAN; PATIENT CARE; PNEUMONIA; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; REVIEW; RISK FACTOR; TREATMENT OUTCOME; UNITED STATES; VIRUS INFECTION; WHEEZING; CHILD; INFANT; NEWBORN; PRESCHOOL CHILD;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFANT; INFANT, NEWBORN; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RIBAVIRIN; RISK FACTORS; UNITED STATES;

EID: 0036633850     PISSN: 10619259     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcm.2002.126434     Document Type: Article

References (15)

1. Ramilio O. Introduction: focus on respiratory syncytial virus. Pediatr Infect Dis J 2000;19:773.
2. Sigurs N, Bjarnason R, Sigurbergson F, Kjellman B. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor in asthma and allergy at age 7. Am J Respir Crit Care Med 2000;161:1501-7.
3. Hall CB. Respiratory syncytial virus: what we know now. Contemp Pediatr 1993;1:11.
4. Hall CB. Pathology and pathogenicity. In: Weisman LE, Groothius JR, editors. A contemporary diagnosis and management of respiratory syncytial virus. Newtown (PA): Handbooks in Healthcare; 2000. p. 72-93.
5. Meissner HC, Welliver RC, Chartrand SA, Law BJ, Weisman LE, Dorkin HL, et al. Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infections in high risk infants: a consensus opinion. Pediatr Infect Dis J 1999;8: 224-31.
6. Fixler DE. Respiratory syncytial virus infection in children with congenital heart disease: a review. Pediatr Cardiol 1996;17:163-8.
7. American Academy of Pediatrics. Committee on Infectious Diseases and Committee on Fetus and Newborn. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IVIG. Pediatrics 1998;102:1211-6.
8. Sanchez PJ. Immunoprophylaxis of respiratory syncytial virus disease. Pediatr Infect Dis J 2000;19:791-801.
9. Groothius JR, Simoes EAF, Levin MJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med 1993; 329:1524-30.
10. Sorrentino M, et al. Effectiveness of palivizumab; evaluation of outcomes from the 1998 to 1999 RSV season. Pediatr Infect Dis J 2000;19:1068-71.
11. Conner EM, the Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102:531-7.
12. Devincenzo JP. Therapy of respiratory syncytial virus. Pediatr Infect Dis J 2000;10(8):786-90.
13. Smith DW, Frankel LR, Mathers LH, et al. A controlled study trial of aerosolized ribavitrin in infants receiving mechanical ventilation for severe respiratory syncytial virus infections. N Engl J Med 1991;325:24.
14. Johnson S, Oliver C, Prince GA, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncitial virus. J Infect Dis 1997;176:1215-24.
15. Piedra PA. Biology and epidemiology of RSV [seminar presentation]. 2001 Sept 8, Houston, Texas.